[go: up one dir, main page]

AU2003210347A1 - Cathepsin y for the treatment of pain - Google Patents

Cathepsin y for the treatment of pain

Info

Publication number
AU2003210347A1
AU2003210347A1 AU2003210347A AU2003210347A AU2003210347A1 AU 2003210347 A1 AU2003210347 A1 AU 2003210347A1 AU 2003210347 A AU2003210347 A AU 2003210347A AU 2003210347 A AU2003210347 A AU 2003210347A AU 2003210347 A1 AU2003210347 A1 AU 2003210347A1
Authority
AU
Australia
Prior art keywords
cathepsin
pain
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003210347A
Inventor
Hermann Lubbert
Beate Schmitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofrontera Bioscience GmbH
Original Assignee
Biofrontera Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofrontera Pharmaceuticals GmbH filed Critical Biofrontera Pharmaceuticals GmbH
Publication of AU2003210347A1 publication Critical patent/AU2003210347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003210347A 2003-02-25 2003-02-25 Cathepsin y for the treatment of pain Abandoned AU2003210347A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/001902 WO2004077053A1 (en) 2003-02-25 2003-02-25 Cathepsin y for the treatment of pain

Publications (1)

Publication Number Publication Date
AU2003210347A1 true AU2003210347A1 (en) 2004-09-17

Family

ID=32921551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003210347A Abandoned AU2003210347A1 (en) 2003-02-25 2003-02-25 Cathepsin y for the treatment of pain

Country Status (2)

Country Link
AU (1) AU2003210347A1 (en)
WO (1) WO2004077053A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2105742A1 (en) * 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999031256A2 (en) * 1997-12-18 1999-06-24 Immunex Corporation Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
EP1336847B1 (en) * 2002-02-14 2007-12-12 Biofrontera Pharmaceuticals AG Cathepsin Y inhibitors for the development of a medicament for the treatment of pain
EP1336661A1 (en) * 2002-02-14 2003-08-20 Biofrontera Pharmaceuticals AG Multiple genes relevant for the characterisation, diagnosis, and manipulation of neuropatic pain

Also Published As

Publication number Publication date
WO2004077053A1 (en) 2004-09-10

Similar Documents

Publication Publication Date Title
AU2003300791A1 (en) Combination therapy for the treatment of pain
GB0213869D0 (en) The treatment of pain
AU2002319286A1 (en) Skin treatment
GB0300428D0 (en) Medical treatment
GB0201025D0 (en) The treatment of degenerative diseases
AU2003210347A1 (en) Cathepsin y for the treatment of pain
GB0307472D0 (en) Medical treatment
AU2003274359A1 (en) Treatment of fluids
GB0306165D0 (en) Medical treatment
GB0325957D0 (en) The treatment of pain
AU2003906654A0 (en) Medical treatment
GB0322014D0 (en) The treatment of pain
HK1089982A (en) Treatment of amyloid-and epileptogenesis-associated diseases
AU2002327697A1 (en) Compounds for the treatment of pain
HK1094506A (en) Cardioelectromagnetic treatment
HK1063015A (en) Carbamate compounds for use in the treatment of pain
AU2003242826A1 (en) Blood treatment
GB0216978D0 (en) The treatment of pain
GB0301526D0 (en) Medical treatment
GB0306626D0 (en) Medical treatment
GB0301519D0 (en) Medical treatment
GB0301521D0 (en) Medical treatment
GB0301522D0 (en) Medical treatment
GB0301524D0 (en) Medical treatment
GB0301515D0 (en) Medical treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase